Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
1.700
+0.030 (1.80%)
At close: Oct 29, 2024, 4:00 PM
1.670
-0.030 (-1.76%)
After-hours: Oct 29, 2024, 7:15 PM EDT
Salarius Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | - | - | - | 1.84 | 5.23 | 3.47 | |
Revenue Growth (YoY) | - | - | - | -64.84% | 51.03% | 77.57% | |
Cost of Revenue | - | - | - | 8.55 | 6.91 | 4.02 | |
Gross Profit | - | - | - | -6.71 | -1.68 | -0.55 | |
Selling, General & Admin | 5.19 | 5.72 | 7.14 | 6.1 | 6.11 | 7.71 | |
Research & Development | 1.55 | 7.17 | 15.84 | - | - | - | |
Operating Expenses | 6.74 | 12.89 | 22.98 | 6.1 | 6.11 | 7.71 | |
Operating Income | -6.74 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | |
Interest & Investment Income | 0.28 | 0.35 | 0.22 | - | - | 0.02 | |
Other Non Operating Income (Expenses) | - | - | 0.01 | 0.04 | 0.43 | 1.31 | |
EBT Excluding Unusual Items | -6.46 | -12.54 | -22.74 | -12.77 | -7.35 | -6.94 | |
Impairment of Goodwill | - | - | -8.87 | - | - | - | |
Pretax Income | -6.46 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | |
Net Income | -6.46 | -12.54 | -31.61 | -12.77 | -7.35 | -6.94 | |
Preferred Dividends & Other Adjustments | - | - | - | - | 0.4 | - | |
Net Income to Common | -6.46 | -12.54 | -31.61 | -12.77 | -7.75 | -6.94 | |
Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | |
Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | |
Shares Change (YoY) | 69.10% | 53.66% | 28.40% | 165.53% | 376.61% | - | |
EPS (Basic) | -12.42 | -30.74 | -119.02 | -61.73 | -99.48 | -424.42 | |
EPS (Diluted) | -12.42 | -30.74 | -119.02 | -61.73 | -100.00 | -424.42 | |
Free Cash Flow | -7.69 | -12.85 | -17.6 | -10.2 | -10.31 | -11.58 | |
Free Cash Flow Per Share | -14.77 | -31.48 | -66.26 | -49.32 | -132.41 | -708.57 | |
Gross Margin | - | - | - | - | -32.11% | -15.99% | |
Operating Margin | - | - | - | -696.27% | -148.78% | -238.53% | |
Profit Margin | - | - | - | -693.84% | -148.06% | -200.18% | |
Free Cash Flow Margin | - | - | - | -554.29% | -197.08% | -334.20% | |
EBITDA | -6.73 | -12.88 | -22.97 | -12.79 | -7.77 | -8.25 | |
EBITDA Margin | - | - | - | - | -148.44% | -238.02% | |
D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | |
EBIT | -6.74 | -12.89 | -22.98 | -12.81 | -7.79 | -8.27 | |
EBIT Margin | - | - | - | - | -148.78% | -238.53% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.